Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2008-03-12
- Lead Sponsor
- Università Politecnica delle Marche
- Target Recruit Count
- 103
- Registration Number
- NCT00633542
- Locations
- 🇮🇹
Clinica di ematologia ospedali riuniti ancona università politecnica delle marche, Ancona, Italy
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 306
- Registration Number
- NCT00602641
- Locations
- 🇺🇸
Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Marietta Memorial Hospital, Marietta, Ohio, United States
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2011-02-09
- Lead Sponsor
- Nordic Myeloma Study Group
- Target Recruit Count
- 300
- Registration Number
- NCT00602511
- Locations
- 🇳🇴
Trondheim University Hospital, Trondheim, Norway
🇩🇰Herlev University Hospital, Herlev, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 25
- Registration Number
- NCT00600028
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Effects of Exercise in Combination With Epoetin Alfa
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 120
- Registration Number
- NCT00577096
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 177
- Registration Number
- NCT00572169
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas, United States
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 5
- Registration Number
- NCT00538824
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-10-03
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 26
- Registration Number
- NCT00538733
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- George A. Kaysen, M.D.
- Target Recruit Count
- 16
- Registration Number
- NCT00529633
- Locations
- 🇺🇸
Beth Israel Medical Center, New York, New York, United States
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00527657
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.